ConductScience.org, home

Paper28889792

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Wolchok JD and 32 others. N Engl J Med, 2017. Cited by 2,966 papers, by iCite.

Cite this record

ConductScience Library. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. Papers, record 28889792. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28889792

Download JSON
Disease
melanoma589 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
PubMed
Journal
N Engl J Med
PubMed
Year
2017
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
2,966
iCite
Relative citation ratio, by iCite
97.9
iCite
Revised in PubMed
2026-07-01
PubMed

Authors33

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wolchok JDJedd D
2Chiarion-Sileni VVanna
3Gonzalez RRene
4Rutkowski PPiotr
5Grob JJJean-Jacques
6Cowey CLC Lance
7Lao CDChristopher D
8Wagstaff JJohn
9Schadendorf DDirk
10Ferrucci PFPier F
11Smylie MMichael
12Dummer RReinhard
13Hill AAndrew
14Hogg DDavid
15Haanen JJohn
16Carlino MSMatteo S
17Bechter OOliver
18Maio MMichele
19Marquez-Rodas IIvan
20Guidoboni MMassimo

Source PubMed

See all 33 authorsDownload CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
MelanomaMajor topic
Skin NeoplasmsMajor topic
Adult
Aged
Disease-Free Survival
Double-Blind Method
Humans
Ipilimumab
Kaplan-Meier Estimate
Middle Aged
Neoplasm Staging
Nivolumab
Survival Rate

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials6

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01844505Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)Derived from the trialYesClinicalTrials.gov
NCT03651271Nivolumab With or Without Ipilimumab in Advanced Metastatic CancerBackgroundClinicalTrials.gov
NCT04165967Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for MelanomaBackgroundClinicalTrials.gov
NCT05235737The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With PembrolizumabBackgroundClinicalTrials.gov
NCT06566391Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic MelanomaBackgroundClinicalTrials.gov
NCT07774247Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular CarcinomaBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections7

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in31442371
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy; Genetic Basis for Clinical Response to CTLA-4 Blockade; Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma; Nivolumab plus Ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma; Hepatotoxicity with Combination of Vemurafenib and Ipilimumab.
https://conductscience.org/library/papers/31442371PubMed
Comment in29265785Nivolumab and Ipilimumab in Advanced Melanoma.https://conductscience.org/library/papers/29265785PubMed
Comment in29265786Nivolumab and Ipilimumab in Advanced Melanoma.https://conductscience.org/library/papers/29265786PubMed
Comment in29360923First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma.https://conductscience.org/library/papers/29360923PubMed
Comment in29668089A new era of proactive melanoma therapy: hit hard, hit early.https://conductscience.org/library/papers/29668089PubMed
Comment in29766492
Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-56.
https://conductscience.org/library/papers/29766492PubMed
Comment in36394225Immunotherapy Combinations Proliferating in Immuno-Oncology.https://conductscience.org/library/papers/36394225PubMed

Download CSV of comments and corrections

References10

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116579821Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis.J Eval Clin Pract2006https://conductscience.org/library/papers/16579821PubMed
225891304Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med2015https://conductscience.org/library/papers/25891304PubMed
325667295Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.J Clin Oncol2015https://conductscience.org/library/papers/25667295PubMed
420525992Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med2010https://conductscience.org/library/papers/20525992PubMed
521639810Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.N Engl J Med2011https://conductscience.org/library/papers/21639810PubMed
627622997Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.Lancet Oncol2016https://conductscience.org/library/papers/27622997PubMed
728475671Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.Ann Oncol2017https://conductscience.org/library/papers/28475671PubMed
825891173Pembrolizumab versus Ipilimumab in Advanced Melanoma.N Engl J Med2015https://conductscience.org/library/papers/25891173PubMed
926027431Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med2015https://conductscience.org/library/papers/26027431PubMed
1010877287Time-dependent ROC curves for censored survival data and a diagnostic marker.Biometrics2000https://conductscience.org/library/papers/10877287PubMed

Download CSV of references

Cited by2,016

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,966 citations.

PMIDTitleJournalYearIn PapersSource
42979397
Immunobiology and Immune-Related Toxicities of Cancer Immunotherapy: Organ-Specific Immune-Related Adverse Events, Cytokine Release Syndrome, and Immune Effector Cell-Associated Neurotoxicity Syndrome.
J Brown Hosp Med2026https://conductscience.org/library/papers/42979397PubMed
42964829Non-invasive electromagnetic fields induce anti-tumor neutrophil reprogramming and enhance checkpoint blockade in breast cancer.Front Immunol2026https://conductscience.org/library/papers/42964829PubMed
42964611Interleukin-21 expressing oncolytic vaccinia virus elicits systemic anti-tumor immune response and synergizes with immunotherapies.Mol Ther Oncol2026https://conductscience.org/library/papers/42964611PubMed
42964167An m5C-associated NSUN5-YBX1-CENPF programme marks melanoma cell states and immune features.Front Immunol2026https://conductscience.org/library/papers/42964167PubMed
42938860Reprogramming the Melanoma Tumor Microenvironment: From Cellular Crosstalk to Cellular Immunotherapy.Cancers (Basel)2026https://conductscience.org/library/papers/42938860PubMed
42934318Safety and efficacy of dual immune checkpoint inhibition for melanoma brain metastases and its comparison to ICI monotherapy: A systematic review and meta-analysis.Neurosurg Rev2026https://conductscience.org/library/papers/42934318PubMed
42927598Peripheral immune tolerance as a driver of tumor immune escape and therapy resistance.Clin Transl Oncol2026https://conductscience.org/library/papers/42927598PubMed
42920926Optimising cancer immunotherapy and emerging data supporting de-escalation strategies.BMJ Oncol2026https://conductscience.org/library/papers/42920926PubMed
42913630Lifestyle-induced regulatory T cell fragility primes adverse events after immune checkpoint blockade.Cell2026https://conductscience.org/library/papers/42913630PubMed
42897893Advances in Chemotherapeutic Potential of Glycoconjugates against Cancer.Anticancer Agents Med Chem2026https://conductscience.org/library/papers/42897893PubMed
42866251Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience2026https://conductscience.org/library/papers/42866251PubMed
42854695Spatially tuned localization of interleukins and OX40 agonists enhances synergistic anti-tumor immunity.Cell Rep Med2026https://conductscience.org/library/papers/42854695PubMed
42833860Poliosis predicts durable response to immune-checkpoint blockade in metastatic melanoma: a multicenter cohort study.J Immunother Cancer2026https://conductscience.org/library/papers/42833860PubMed
42797500Therapeutic Resistance in Melanoma: Molecular Mechanisms and Emerging Pharmaceutical Strategies.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42797500PubMed
42795023Management of Melanoma in Advanced Age: A Comprehensive Literature Review of Tumor Biology, Systemic Therapies and Geriatric Challenges.Cancers (Basel)2026https://conductscience.org/library/papers/42795023PubMed
42750158Spatiotemporally Controlled Sequential Chemo-Immunotherapy Activates Pyroptosis for Robust Anti-Tumor Immunotherapy.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42750158PubMed
42738322From Pixels to Stroma: AI-Driven Spatial Profiling of Cancer-Associated Fibroblasts on H&E and Its Implications for Immunotherapy.Cancers (Basel)2026https://conductscience.org/library/papers/42738322PubMed
42729917Immune checkpoint inhibitor treatment - real-world use and outcomes in Sweden 2015-2023.Ups J Med Sci2026https://conductscience.org/library/papers/42729917PubMed
42705865Anti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities.J Immunother Cancer2026https://conductscience.org/library/papers/42705865PubMed
42699924Primary gastric melanoma in an Asian patient: a rare case report of early detection and therapeutic uncertainty.Int J Surg Case Rep2026https://conductscience.org/library/papers/42699924PubMed

See all 2,016 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
CXCL103627PubTator's text mininghttps://conductscience.org/library/genes/3627NCBI Gene
CXCL94283PubTator's text mininghttps://conductscience.org/library/genes/4283NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
IPILIMUMABCHEMBL1789844Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1789844ChEMBL
NIVOLUMABCHEMBL2108738Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2108738ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28889792

GET https://conductscience.org/api/papers/v1/28889792/authors?page=2